Analysts Set Expectations for Gilead Sciences, Inc.’s Q2 2022 Earnings (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) – Research analysts at SVB Leerink issued their Q2 2022 earnings per share estimates for shares of Gilead Sciences in a research note issued to investors on Sunday, May 22nd. SVB Leerink analyst G. Porges anticipates that the biopharmaceutical company will post earnings per share of $1.55 for the quarter. SVB Leerink has a “Market Perform” rating and a $68.00 price target on the stock. SVB Leerink also issued estimates for Gilead Sciences’ Q3 2022 earnings at $1.52 EPS, Q3 2022 earnings at $1.52 EPS, Q4 2022 earnings at $1.36 EPS, FY2022 earnings at $6.56 EPS, FY2022 earnings at $6.56 EPS, Q1 2023 earnings at $1.74 EPS, FY2023 earnings at $6.75 EPS, FY2024 earnings at $6.83 EPS and FY2024 earnings at $6.83 EPS.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.35. Gilead Sciences had a return on equity of 44.98% and a net margin of 16.43%. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.28 billion. During the same quarter in the previous year, the business earned $2.08 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year.

A number of other analysts have also weighed in on GILD. Morgan Stanley cut their price objective on Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 12th. Bank of America cut their price target on Gilead Sciences from $73.00 to $71.00 and set a “neutral” rating on the stock in a report on Wednesday, February 2nd. StockNews.com started coverage on Gilead Sciences in a research note on Thursday, March 31st. They issued a “buy” rating for the company. Barclays lowered their price target on shares of Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a report on Thursday, March 10th. Finally, Piper Sandler decreased their price objective on shares of Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating for the company in a research report on Monday, May 16th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, Gilead Sciences has an average rating of “Hold” and an average target price of $72.20.

Shares of GILD stock opened at $64.35 on Wednesday. Gilead Sciences has a fifty-two week low of $57.19 and a fifty-two week high of $74.12. The company has a 50 day moving average price of $61.31 and a 200 day moving average price of $65.12. The stock has a market capitalization of $80.72 billion, a P/E ratio of 17.97, a price-to-earnings-growth ratio of 0.45 and a beta of 0.38. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.30 and a current ratio of 1.48.

Several large investors have recently added to or reduced their stakes in GILD. Morgan Stanley raised its position in Gilead Sciences by 18.3% in the second quarter. Morgan Stanley now owns 10,989,872 shares of the biopharmaceutical company’s stock worth $756,765,000 after acquiring an additional 1,702,366 shares in the last quarter. Keudell Morrison Wealth Management boosted its holdings in Gilead Sciences by 4.5% during the third quarter. Keudell Morrison Wealth Management now owns 10,727 shares of the biopharmaceutical company’s stock worth $749,000 after buying an additional 458 shares in the last quarter. EagleClaw Capital Managment LLC grew its position in Gilead Sciences by 1.2% during the third quarter. EagleClaw Capital Managment LLC now owns 42,870 shares of the biopharmaceutical company’s stock worth $2,993,000 after buying an additional 516 shares during the period. B. Riley Wealth Management Inc. acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $293,000. Finally, Hennion & Walsh Asset Management Inc. increased its stake in Gilead Sciences by 9.1% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 5,589 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 464 shares in the last quarter. 80.16% of the stock is currently owned by institutional investors and hedge funds.

In related news, EVP Brett A. Pletcher sold 3,634 shares of the stock in a transaction on Friday, March 11th. The shares were sold at an average price of $58.24, for a total transaction of $211,644.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 29th. Shareholders of record on Wednesday, June 15th will be issued a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a dividend yield of 4.54%. The ex-dividend date of this dividend is Tuesday, June 14th. Gilead Sciences’s payout ratio is 81.56%.

Gilead Sciences Company Profile (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Further Reading

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.